Yasheng Pharmaceutical announced that the global registration phase III clinical study of the company's original Class 1 drug olevatinib combined with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphocytic leukemia patients was approved by the US Food and Drug Administration and the European Medicines Agency. As Nellick's second Global Registration Phase III study approved by European and American regulators, the POLARIS-1 study was simultaneously enrolled in multiple centers in multiple countries, which will accelerate Nellick's listing process globally, especially in the European and American markets.

Yasheng Pharmaceutical announced that the global registration phase III clinical study of the company's original Class 1 drug olevatinib combined with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphocytic leukemia patients was approved by the US Food and Drug Administration and the European Medicines Agency. As Nellick's second Global Registration Phase III study approved by European and American regulators, the POLARIS-1 study was simultaneously enrolled in multiple centers in multiple countries, which will accelerate Nellick's listing process globally, especially in the European and American markets.